NCT00726232View on ClinicalTrials.gov

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

PHASE2TerminatedINTERVENTIONAL

Enrollment

73

Participants

Timeline

Start Date

August 20, 2008

Primary Completion Date

June 20, 2010

Study Completion Date

August 20, 2018

Conditions

Myeloproliferative Neoplasm (MPN)

Interventions

DRUG

Ruxolitinib

Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.

Trial Locations (4)

77030

Houston

Unknown

Bergamo

Florence

Pavia

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY